A new study conducted by American researchers at the University of Buffalo in New York has shown that the treatment "Ozempic" helps to reduce the risk of pancreatitis in patients with obesity and type 2 diabetes. Dr. Mahmoud Nassar, a professor at the university and the principal investigator of the study, stated, "Our study highlights the safety and potential of GLP-1 receptor agonist medications to reduce the risk of recurrent acute pancreatitis in patients with obesity and type 2 diabetes, offering new hope for effective treatment."
The researchers analyzed data from 638,000 patients who had previously suffered from pancreatitis across 15 countries, but were based in the United States. They tracked how many patients experienced a recurrence of pancreatitis after starting treatment with Ozempic or other medications for diabetes and obesity.
The results concluded that pancreatitis recurred in 15% of patients who took Ozempic, compared to 24% in the group receiving "SGLT2 inhibitors," 23% in the "DPP-4 inhibitor" group, and 52% of patients who did not take any medication at all.
